NCT01928225View on ClinicalTrials.gov

Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

PHASE2CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

September 2, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

March 1, 2018

Conditions

Cervical High Grade Squamous Intraepithelial Lesion

Interventions

BIOLOGICAL

Human Papillomavirus vaccine

The participants receive the qHPV vaccine at entry, week 4 and week 26

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Witwatersrand, South Africa

OTHER

NCT01928225 - Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL | Biotech Hunter | Biotech Hunter